BioLine Rx Ltd logo

BioLine Rx Ltd

XTAE:BLRX (Israel)  
₪ 0.16 (-1.23%) May 16
At Loss
P/B:
3.58
Market Cap:
₪ 193.05M ($ 52.11M)
Enterprise V:
₪ 77.73M ($ 20.98M)
Volume:
712.44K
Avg Vol (2M):
1.99M
Also Trade In:
Volume:
712.44K
At Loss
Avg Vol (2M):
1.99M

Business Description

Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Name Current Vs Industry Vs History
Cash-To-Debt 3.71
Equity-to-Asset 0.21
Debt-to-Equity 0.88
Debt-to-EBITDA -0.2
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -10.57
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 35.7
9-Day RSI 34.18
14-Day RSI 32.42
6-1 Month Momentum % -59.62
12-1 Month Momentum % -45.34

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.53
Quick Ratio 1.47
Cash Ratio 1.39
Days Sales Outstanding 27.22

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -46
Shareholder Yield % -10.49

Financials (Next Earnings Date:2024-05-24 Est.)

XTAE:BLRX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BioLine Rx Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪) 17.782
EPS (TTM) (₪) -0.222
Beta 0
Volatility % 79.61
14-Day RSI 32.42
14-Day ATR (₪) 0.012405
20-Day SMA (₪) 0.16885
12-1 Month Momentum % -45.34
52-Week Range (₪) 0.151 - 0.7
Shares Outstanding (Mil) 1,199.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BioLine Rx Ltd Filings

Filing Date Document Date Form
No Filing Data

BioLine Rx Ltd Stock Events

Financials Calendars
Event Date Price(₪)
No Event Data

BioLine Rx Ltd Frequently Asked Questions

What is BioLine Rx Ltd(XTAE:BLRX)'s stock price today?
The current price of XTAE:BLRX is ₪0.16. The 52 week high of XTAE:BLRX is ₪0.70 and 52 week low is ₪0.15.
When is next earnings date of BioLine Rx Ltd(XTAE:BLRX)?
The next earnings date of BioLine Rx Ltd(XTAE:BLRX) is 2024-05-24 Est..
Does BioLine Rx Ltd(XTAE:BLRX) pay dividends? If so, how much?
BioLine Rx Ltd(XTAE:BLRX) does not pay dividend.

Press Release

Subject Date
No Press Release